Renier Brentjens, MD, PhD

home / authors / renier-brentjens-md-phd

Articles

Dr. Brentjens Discusses the Goal of Armored CAR T Cells

March 9th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the goal of armored chimeric antigen receptor (CAR) T cells.

Dr. Brentjens Discusses Toxicities Associated With CAR T-Cell Therapy

Renier Brentjens, MD, PhD

February 5th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Brentjens Discusses Potential for CAR T-Cell Therapy in Solid Tumors

Renier Brentjens, MD, PhD

January 25th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential for chimeric antigen receptor therapy (CAR) T-cell therapy in solid tumors.

Dr. Brentjens on Obstacles with CAR T-Cell Therapy in Hematologic Malignancies

Renier Brentjens, MD, PhD

January 17th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses challenges facing chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies.

Dr. Brentjens on Research Beyond CD19 in CAR T-Cell Therapy

Renier Brentjens, MD, PhD

January 5th 2018

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for CAR T-cell therapy.